PPARγ and chronic kidney disease.

Area of Science:

• Pharmacology
• Nephrology
• Endocrinology

Background:

• Peroxisome proliferator-activated receptor-γ (PPARγ) agonists, like thiazolidinediones (TZDs), are established treatments for type 2 diabetes, improving insulin sensitivity and lipid metabolism.
• PPARγ receptors, members of the nuclear receptor superfamily, regulate gene expression via PPAR response elements.
• Emerging evidence suggests PPARγ agonists possess effects beyond metabolic regulation, impacting various cellular pathways.

Purpose of the Study:

• To review the evidence for the therapeutic effects of TZDs in nondiabetic chronic kidney disease (CKD).
• To explore the mechanisms by which PPARγ agonists may benefit kidney health in experimental and human CKD models.
• To assess the impact of TZDs on fibrotic, inflammatory, immune, and oxidative stress pathways in CKD.

Main Methods:

• Literature review of experimental studies and human clinical trials.
• Analysis of research investigating the effects of PPARγ agonists on renal cells and pathways.
• Focus on studies examining TZDs in nondiabetic CKD settings.

Main Results:

• PPARγ agonists demonstrate pleiotropic effects in preclinical and clinical settings, extending beyond their known metabolic actions.
• These agents modulate key pathogenic pathways in CKD, including renal fibrosis, inflammation, immune responses, and oxidative stress.
• Evidence suggests potential renoprotective roles for TZDs in various forms of kidney disease.

Conclusions:

• TZDs exhibit multifaceted therapeutic potential in chronic kidney disease, irrespective of diabetic status.
• Their ability to target multiple fibrotic, inflammatory, and oxidative pathways presents a promising avenue for CKD management.
• Further investigation into TZDs for nondiabetic CKD is warranted based on current evidence.